The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
2-ethylhexyldiphenylphosphate results in increased expression of ADIPOQ mRNA [2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of ADM mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of ADM2 mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of APLNR mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of ASNS mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of ATF4 mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of C3AR1 mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of CDH5 mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of COL10A1 mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of COL13A1 mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of COL24A1 mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of CSF1R mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of CTH mRNA
[tris(2-butoxyethyl) phosphate co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with santicizer 148 co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of CYP11A1 mRNA
[tris(2-butoxyethyl) phosphate co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with santicizer 148 co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of CYP19A1 mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of DDIT3 mRNA
2-ethylhexyldiphenylphosphate results in increased expression of FABP4 mRNA [2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA; [2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 protein; MIR155 inhibits the reaction [[2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA]
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of FGF21 mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of FLCN mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of GDF15 mRNA
[tris(2-butoxyethyl) phosphate co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with santicizer 148 co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] inhibits the reaction [Bucladesine results in increased expression of HMGCR mRNA]
2-ethylhexyldiphenylphosphate results in increased expression of HSD3B1 mRNA PPARG protein affects the reaction [2-ethylhexyldiphenylphosphate results in increased expression of HSD3B1 mRNA]
2-ethylhexyldiphenylphosphate binds to IGF1R protein 2-ethylhexyldiphenylphosphate results in decreased phosphorylation of IGF1R protein 2-ethylhexyldiphenylphosphate results in decreased activity of and results in decreased phosphorylation of IGF1R protein
[2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of MIR155 mRNA; [2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of MIR335 mRNA; [2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA; [2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA; [2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 protein; [2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of LPL mRNA; [2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of MIR193A mRNA; [2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of MIR205 mRNA; [2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of MIR708 mRNA; [2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA; [2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG protein; MIR155 inhibits the reaction [[2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA]
2-ethylhexyldiphenylphosphate results in increased expression of LPL mRNA [2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of LPL mRNA
[2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of MIR155 mRNA; MIR155 inhibits the reaction [[2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA]
[2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of MIR193A mRNA
[2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of MIR205 mRNA
[2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of MIR708 mRNA
2-ethylhexyldiphenylphosphate inhibits the reaction [T0901317 results in increased activity of NR1H2 protein]; [Dust results in increased abundance of 2-ethylhexyldiphenylphosphate] inhibits the reaction [T0901317 results in increased activity of NR1H2 protein]
2-ethylhexyldiphenylphosphate inhibits the reaction [T0901317 results in increased activity of NR1H3 protein]; [Dust results in increased abundance of 2-ethylhexyldiphenylphosphate] inhibits the reaction [T0901317 results in increased activity of NR1H3 protein]
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of PCK2 mRNA
2-ethylhexyldiphenylphosphate binds to and results in increased activity of PPARG protein; [2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA; [2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG protein 2-ethylhexyldiphenylphosphate results in increased activity of PPARG protein PPARG protein affects the reaction [2-ethylhexyldiphenylphosphate results in increased expression of HSD3B1 mRNA]
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of PTPRB mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of RUNX2 mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of RUNX3 mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of SMPD3 mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of SP7 mRNA
[tris(2-butoxyethyl) phosphate co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with santicizer 148 co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; [tris(2-butoxyethyl) phosphate co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with santicizer 148 co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of STAR mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of TRIB3 mRNA
browse the term
